Structural and functional features of human muscle-tendon unit
In this situation, compounding is necessary to provide the patient with a reformulated version that omits the allergen
Instead, the weight loss achieved in the clinical trials was the result of months of support from doctors, dietitians, physical activity advisors, nurses etc
Key findings from this phase 2 obesity trial included: Mean weight reduction of up to approximately 24.2% at the highest dose (12 mg) after 48 weeks Dose-dependent reductions in body weight across all active treatment arms Significant reductions in waist circumference, blood pressure, and lipid parameters Improvements in fasting glucose and insulin resistance markers A separate phase 2 trial in adults with type 2 diabetes (published in 2023) demonstrated meaningful HbA1c reductions alongside substantial weight loss, suggesting potential dual utility in both obesity and glycaemic management
Initial investigations into the causes of adult onset GHD showed them to result from damage to the pituitary gland due to tumors, surgery or radiotherapy that disrupted function of the GH neuroendocrine axis
Clinical Applications
